RS
IBRX icon

R Squared’s ImmunityBio IBRX Stock Holding History

R Squared’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,180
Closed -$69.7K – 573
2025
Q4 		$69.7K Buy
35,180
+17,710
+101% +$40.1K 0.03% 438
2025
Q3 		$43K Buy
+17,470
New +$45K 0.02% 502

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

R Squared's IBRX Position: Q1 2026 in Review

R Squared sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 35,180 shares — an estimated $69.7K sold.

R Squared first reported a position in IBRX in Q3 2025 and held it in 2 quarters. The position peaked at $69.7K in Q4 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • R Squared reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
  • R Squared sold 35,180 ImmunityBio shares in Q1 2026, an estimated $69.7K.
  • R Squared first reported a position in ImmunityBio in Q3 2025 and held it in 2 quarters.
  • R Squared's ImmunityBio position peaked at $69.7K in Q4 2025.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.